Cargando…

Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer

With recent advancements in a non-invasive approach to cancer diagnosis and surveillance, the term “liquid biopsy” has gained traction but is currently limited by technological challenges in identifying and isolating circulating tumor cells (CTCs), proteins, cell-free DNA (cfDNA), or other nucleic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Satyal, Uttam, Srivastava, Abhishek, Abbosh, Philip H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877686/
https://www.ncbi.nlm.nih.gov/pubmed/31803629
http://dx.doi.org/10.3389/fonc.2019.01266
_version_ 1783473385029763072
author Satyal, Uttam
Srivastava, Abhishek
Abbosh, Philip H.
author_facet Satyal, Uttam
Srivastava, Abhishek
Abbosh, Philip H.
author_sort Satyal, Uttam
collection PubMed
description With recent advancements in a non-invasive approach to cancer diagnosis and surveillance, the term “liquid biopsy” has gained traction but is currently limited by technological challenges in identifying and isolating circulating tumor cells (CTCs), proteins, cell-free DNA (cfDNA), or other nucleic acids. Tumor tissue biopsy, especially in genitourinary (GU) system is sometimes inadequate and requires invasive surgical options, especially for upper tract urothelial cancer. Urine can prove to be “liquid gold” since it may be a more abundant source of tumor-derived material without the background noise; however, urine DNA (uDNA) may be associated with low mutant allele fraction (MAF). Molecular detection of mutations in uDNA requires a sensitive and accurate method of analysis that allows a high depth of sequencing while minimizing artifacts. Several sequencing approaches to address this hurdle using enhanced library preparation techniques such as Tagged amplicon deep sequencing (TAm-Seq), Safe-SeqS, FAST-SeqS, and CAPP-Seq approaches have been developed. Urine biopsy utilizing next-generation sequencing (NGS) can prove useful at all stages of urologic malignancy care, where urine can be collected to aid in clinical decision making through the identification of commonly known mutations, and potentially reduce or avoid all forms of invasive procedures.
format Online
Article
Text
id pubmed-6877686
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68776862019-12-04 Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer Satyal, Uttam Srivastava, Abhishek Abbosh, Philip H. Front Oncol Oncology With recent advancements in a non-invasive approach to cancer diagnosis and surveillance, the term “liquid biopsy” has gained traction but is currently limited by technological challenges in identifying and isolating circulating tumor cells (CTCs), proteins, cell-free DNA (cfDNA), or other nucleic acids. Tumor tissue biopsy, especially in genitourinary (GU) system is sometimes inadequate and requires invasive surgical options, especially for upper tract urothelial cancer. Urine can prove to be “liquid gold” since it may be a more abundant source of tumor-derived material without the background noise; however, urine DNA (uDNA) may be associated with low mutant allele fraction (MAF). Molecular detection of mutations in uDNA requires a sensitive and accurate method of analysis that allows a high depth of sequencing while minimizing artifacts. Several sequencing approaches to address this hurdle using enhanced library preparation techniques such as Tagged amplicon deep sequencing (TAm-Seq), Safe-SeqS, FAST-SeqS, and CAPP-Seq approaches have been developed. Urine biopsy utilizing next-generation sequencing (NGS) can prove useful at all stages of urologic malignancy care, where urine can be collected to aid in clinical decision making through the identification of commonly known mutations, and potentially reduce or avoid all forms of invasive procedures. Frontiers Media S.A. 2019-11-19 /pmc/articles/PMC6877686/ /pubmed/31803629 http://dx.doi.org/10.3389/fonc.2019.01266 Text en Copyright © 2019 Satyal, Srivastava and Abbosh. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Satyal, Uttam
Srivastava, Abhishek
Abbosh, Philip H.
Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
title Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
title_full Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
title_fullStr Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
title_full_unstemmed Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
title_short Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
title_sort urine biopsy—liquid gold for molecular detection and surveillance of bladder cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877686/
https://www.ncbi.nlm.nih.gov/pubmed/31803629
http://dx.doi.org/10.3389/fonc.2019.01266
work_keys_str_mv AT satyaluttam urinebiopsyliquidgoldformoleculardetectionandsurveillanceofbladdercancer
AT srivastavaabhishek urinebiopsyliquidgoldformoleculardetectionandsurveillanceofbladdercancer
AT abboshphiliph urinebiopsyliquidgoldformoleculardetectionandsurveillanceofbladdercancer